登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：600195 股票简称：中牧股份 编号：临2025-035 中牧实业股份有限公司 第九届董事会2025年第十三次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"或"中牧股份"）第九届董事会2025年第十三次临时会议通知于 2025年11月13日以电话、口头等通讯方式送达，全体董事一致同意豁免本次会议的通知期限，会议于 2025年11月13日在北京市丰台区总部基地八区16号楼801会议室以现场结合视频的方式召开。会议应到 董事7名，实到董事7名。会议由董事长吴冬荀先生主持，符合《公司法》《公司章程》的规定。 经与会董事审议，会议表决通过如下议案： 一、关于修订《中牧实业股份有限公司董事会审计委员会议事规则》的议案 表决结果：7票同意，0票反对，0票弃权。 同意修订《中牧实业股份有限公司董事会审计委员会议事规则》部分条款。 本议案在提交董事会前已经公司董事会审计委员会审议通过。 修订后的《中牧实业股份有限公司董事会审 ...

Core Insights - The Inner Mongolia Autonomous Region's technology transaction post-subsidy program has allocated 68.92 million yuan to support 856 technology transfer projects, enhancing the conversion of scientific achievements into practical applications [1] - The program aims to provide incentives for technology transfer and related services, targeting three main entities: technology demanders, suppliers, and transfer service institutions [1] - The funding is designed to stimulate technological upgrades in local enterprises, fostering high-quality economic development in the region [1] Group 1: Company Initiatives - Inner Mongolia Jinyu Baoling Biological Pharmaceutical Co., Ltd. has received 1.436 million yuan in post-subsidy funding, which will be directed towards ongoing R&D projects and capacity expansion [2] - The company is collaborating with Guangdong Lanyu Biotechnology Co., Ltd. and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. to develop advanced vaccines, enhancing its technological capabilities and market competitiveness [2] - The funding is expected to support the health of the livestock breeding industry by ensuring the effective application of new technologies [2] Group 2: Industry Impact - The post-subsidy program has been tailored to meet the diverse innovation needs across various sectors, including pharmaceuticals, rare earths, and financial services [3][4] - In the pharmaceutical sector, companies like Lianbang Pharmaceutical (Inner Mongolia) Co., Ltd. are using the subsidies for process upgrades and green technology adoption, aiming to improve product quality and sustainability [3] - The rare earth industry is also benefiting, with companies like China Northern Rare Earth Group investing in new materials and technologies to enhance product value [3] Group 3: Policy Effectiveness - The policy is designed to ensure that subsidies are allocated to key innovation areas, such as green processes and digital transformation in service industries [4] - The program facilitates a seamless integration of academic research and industrial needs, exemplified by Inner Mongolia Mengniu Dairy Group's project that combines university resources with market demands [6] - The funding not only reduces innovation risks for companies but also promotes a virtuous cycle of research output, industrial application, and market feedback [7]

Core Insights - The biopharmaceutical industry in Hohhot is experiencing rapid growth, driven by private enterprises and strategic initiatives focused on technological innovation and industrial chain enhancement [1][6] - Hohhot aims to establish itself as a leading hub for green biopharmaceuticals in Northern China, leveraging its industrial advantages to accelerate the transformation and commercialization of new technologies [6] Group 1: Industry Development - Hohhot is cultivating six major industrial clusters with a focus on biopharmaceuticals, achieving significant milestones such as the successful implementation of the world's first mRNA vaccine and intelligent manufacturing projects [1] - The city has over 60 biopharmaceutical companies, 143 innovation platforms, and 117 research institutions, with a projected industry output value of 20.25 billion yuan in 2024, accounting for approximately 7.9% of the city's industrial output [3] Group 2: Technological Innovation - Companies like Jinyu Biotechnology have pioneered technologies in large-scale cell culture and vaccine quality standards, contributing to advancements in vaccine development and production [1][4] - Innovative packaging technologies for fermentation agents and the development of vaccines such as the Brucella vaccine highlight the ongoing technological breakthroughs within the industry [2] Group 3: Collaborative Ecosystem - Hohhot has established a multi-level collaborative innovation ecosystem involving government, industry, academia, and research institutions, focusing on key technologies in animal vaccine production [4] - Partnerships between enterprises and academic institutions have led to significant advancements, such as the establishment of the largest lactic acid bacteria resource bank and successful technology transfers [4] Group 4: Policy Support - The local government has introduced various policies to support high-quality development in the biopharmaceutical sector, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [5]